[Developments in chemotherapy; cytostatic agents with an increased specificity and other forms of administering cytotoxic antineoplastic agents].
In recent years developments in molecular biology have greatly increased our knowledge about the cellular processes which govern the development of cancer. This has led to the development of anticancer agents that specifically target one of these cellular processes, for example, farnesyl transferase inhibitors, receptor tyrosine kinase inhibitors, matrix metalloproteinase inhibitors and anti-angiogenic agents. In addition to this, new chemotherapeutic agents with increased target specificity have been developed. Finally, in recent years there has been an emphasis on developing new forms of administration so that optimal use can be made of existing chemotherapeutic agents.
Eskens
F A
FA
Academisch Ziekenhuis Rotterdam, locatie Daniel den Hoed Kliniek, afd. Interne Oncologie, Postbus 5201, 3008 AE Rotterdam.
de Jonge
M J
MJ
Verweij
J
J
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D004333:Drug Administration Routes; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D051231:Farnesyltranstransferase; D006801:Humans; D008081:Liposomes; D061965:Matrix Metalloproteinase Inhibitors; D009369:Neoplasms / Q000188:drug therapy*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D016032:Randomized Controlled Trials as Topic
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D008081:Liposomes; D061965:Matrix Metalloproteinase Inhibitors; D019883:Alkyl and Aryl Transferases; D051231:Farnesyltranstransferase; D011505:Protein-Tyrosine Kinases